Development of a long-term in vitro assay able to identify compounds that can overcome resistance to CDK4/6 inhibitor plus endocrine therapy in ER+HER2-breast cancer

被引：0
|
作者：
Kronstadt, Stephanie
Umbreit, Neil
Niederst, Matt
Janssens, Rens
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-23-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-23-10
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AI-enhanced high-content imaging to identify effective compound combinations with CDK4/6 inhibitor and endocrine therapy in ER+HER2-breast cancer
    Kronstadt, S.
    Umbreit, N.
    Janssens, R.
    Niederst, M.
    Duong, T.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S87 - S87
  • [2] RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER plus breast cancer
    Kindt, Charlotte K.
    Ehmsen, Sidse
    Traynor, Sofie
    Policastro, Benedetta
    Nissen, Nikoline
    Jakobsen, Mie K.
    Hundebol, Monique F.
    Johansen, Lene E.
    Bak, Martin
    Arbajian, Elsa
    Staaf, Johan
    Ditzel, Henrik J.
    Alves, Carla L.
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [3] EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER plus breast cancer
    Belli, Stefania
    Esposito, Daniela
    Ascione, Claudia M.
    Messina, Francesca
    Napolitano, Fabiana
    Servetto, Alberto
    De Angelis, Carmine
    Bianco, Roberto
    Formisano, Luigi
    CANCER LETTERS, 2024, 593
  • [4] Unveiling mechanisms of CDK4/6 inhibitor resistance in ER plus breast cancer models with acquired resistance
    Li, Bin
    Liu, Gaoxiang
    Ni, Ting
    Shi, Wenting
    Gu, Qingyang
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Longitudinal, multimodal profiling of metastatic ER plus breast cancer on CDK4/6 inhibitor therapy
    Creason, Allison L.
    Egger, Julian
    Watson, Cameron
    Sivagnanam, Shamilene
    Lin, Jia-Ren
    Chin, Koei
    Sorger, Peter K.
    Coussens, Lisa M.
    Mitri, Zahi I.
    Gray, Joe W.
    Mills, Gordon B.
    Goecks, Jeremy
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Metabolic reprogramming of ER plus breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Parri, Matteo
    Malorni, Luca
    Di Leo, Angelo
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 529 - 530
  • [8] Effect of tasurgratinib as an orally available FGFR1-3 inhibitor on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2 (-) breast cancer preclinical models
    Kawano, S.
    Fukushima, S.
    Nishibata, K.
    Gejima, R.
    Miyano, S. Watanabe
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S29 - S29
  • [9] Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study
    Yildirim, E. Caliskan
    Atag, E.
    Yuzugullu, E.
    Unal, O. U.
    Celebi, A.
    Keser, M.
    Uzun, M.
    Keskinkilic, M.
    Simsek, E. Tanrikulu
    Sari, M.
    Yavuzsen, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S378 - S378
  • [10] LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER plus breast cancer
    Jin, Xi
    Ge, Li-Ping
    Li, Qiang
    Zhao, Naiqing
    Di, Gen-Hong
    Xu, Xiao-En
    Jiang, Yizhou
    MOLECULAR CANCER, 2020, 19 (01)
12345